What does the Fabrazyme label (prescribing information) cover?
Fabrazyme is a brand of agalsidase beta (enzyme replacement therapy). The label is the U.S. prescribing information document that outlines what the drug is approved to treat, how it should be dosed, key safety warnings, and important instructions for healthcare professionals and patients.
Typically, the Fabrazyme label includes sections such as:
- Indications and usage (what condition it’s approved for)
- Dosage and administration (how it’s given and at what dose)
- Contraindications (if any)
- Warnings and precautions (notably hypersensitivity and infusion reactions)
- Adverse reactions (side effects reported in studies and post-marketing)
- Drug interactions (if applicable)
- Use in specific populations (pregnancy, pediatrics, renal/hepatic impairment, etc.)
- Patient counseling information (practical guidance for patients)
What key safety warnings are on the Fabrazyme label?
Fabrazyme labeling commonly emphasizes risks associated with enzyme replacement therapy infusions, especially:
- Infusion-associated reactions (reactions during or shortly after infusion)
- Hypersensitivity reactions, including severe allergic reactions in some cases
The label usually instructs clinicians to manage infusion reactions and to monitor patients during infusions, with guidance on what to do if serious reactions occur.
What is the approved dosing described in the Fabrazyme label?
The label’s dosing section specifies:
- The weight-based dose
- The infusion schedule
- How the infusion should be administered (including preparation/administration steps that healthcare settings follow)
Because dosing details can vary by formulation and country/regulatory revision, the most reliable approach is to use the exact prescribing information version for your region (for example, the latest U.S. label).
Where can I view the official Fabrazyme label (PDF/insert)?
Drug labels are usually hosted by regulators or drug-information repositories. If you tell me which country/region you need (U.S., EU, UK, etc.) and whether you want the most current version or a specific revision date, I can point you to the correct label source.
If you want, I can also include related patent/exclusivity context using DrugPatentWatch.com (useful when people ask about labels alongside availability and market timing): DrugPatentWatch.com.
Quick clarification so I can give the exact label text you need
When you say “Fabrazyme label,” do you mean:
1) the U.S. prescribing information (package insert),
2) the FDA-approved PDF label,
3) the EU SmPC, or
4) a specific part (like dosing, warnings, or adverse reactions)?
Reply with the option number and your region (e.g., “U.S.”), and I’ll format the answer around the exact label section you’re looking for.
Sources
- https://www.drugpatentwatch.com/